Search Results - "Merle, Pauline A"

Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia by Hess, Corine J, Feller, Nicole, Denkers, Fedor, Kelder, Angele, Merle, Pauline A, Heinrich, Michael C, Harlow, Amy, Berkhof, Johannes, Ossenkoppele, Gert J, Waisfisz, Quinten, Schuurhuis, Gerrit J

“…1 Department of Hematology, VU University Medical Center, Amsterdam, the Netherlands 2 Department of Pathology and Medicine, Oregon Health and Science…”
Get full text

Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid by Verhagen, Han J.M.P., Smit, Marjon A., Rutten, Arjo, Denkers, Fedor, Poddighe, Pino J., Merle, Pauline A., Ossenkoppele, Gert J., Smit, Linda

“…Enhanced expression of ecotropic viral integration site 1 (EVI-1) occurs in ∼10% of acute myeloid leukemia (AML) patients and is associated with a very poor…”
Get full text

DNA vs cDNA FLT3-ITD allelic ratio and length measurements in adult acute myeloid leukemia by Cucchi, David G.J., Vonk, Christian M., Rijken, Melissa, Kavelaars, François G., Merle, Pauline A., Verhoef, Elvira, Venniker-Punt, Bianca, Kwidama, Zinia J., Gradowska, Patrycja, Löwenberg, Bob, Janssen, Jeroen J.W.M., Cloos, Jacqueline, Valk, Peter J.M.

Get full text

A 51‐year‐old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment by Janssen, Jeroen J.W.M., Berendse, Henk W., Schuurhuis, Gerrit‐Jan, Merle, Pauline A., Ossenkoppele, Gert J.

Get full text

Triple immunofluorescence staining for prediction of relapse in childhood precursor B acute lymphoblastic leukaemia by Vervoordeldonk, S F, Merle, P A, Behrendt, H, Steenbergen, E J, Van Leeuwen, E F, Van den Berg, H, Von dem Borne, A E, Van der Schoot, C E, Slaper-Cortenbach, I C

“…In this study we describe a fast and sensitive method using three-colour immunofluorescence for the detection of cells with phenotypes that are rare in normal…”
Get more information

Immunophenotypical Minimal Residual Disease as a Short Term Endpoint for Monitoring Effects of Targeted Inhibitors in Acute Myeloid Leukemia by Hess, Corine J., Feller, Nicole, Denkers, Fedor, Merle, Pauline A., Ossenkoppele, Gert J., Waisfisz, Quinten, Schuurhuis, Gerrit Jan

“…At present, a large number of clinical trails make use of inhibitors that target leukemia specific defects, such as BCR-ABL, c-kit mutations or tandem…”
Get full text

B precursor acute lymphoblastic leukemia third complementarity-determining regions predominantly represent an unbiased recombination repertoire: leukemic transformation frequently occurs in fetal life by Steenbergen, E J, Verhagen, O J, van Leeuwen, E F, Behrendt, H, Merle, P A, Wester, M R, von dem Borne, A E, van der Schoot, C E

“…To determine whether the ALL (acute lymphoblastic leukemia) CDR3 (third complementarity-determining region) repertoire represents the recombination repertoire,…”
Get more information

Preclinical studies with radiolabeled monoclonal antibodies for treatment of patients with B-cell malignancies by Vervoordeldonk, S F, Merle, P A, van Leeuwen, E F, von dem Borne, A E, Slaper-Cortenbach, I C

“…Studies on radiolabeled monoclonal antibodies (MoAb) have dealt mainly with single antibodies. However, major differences may exist among different…”
Get more information

PCR‐positivity in harvested bone marrow predicts relapse after transplantation with autologous purged bone marrow in children in second remission of precursor B‐cell acute leukaemia by VERVOORDELDONK, SUSAN F., MERLE, PAULINE A., BEHRENDT, HENK, STEENBERGEN, ERIC J., VAN DEN BERG, HENK, VAN WERING, ELISABETH R., KR. VON DEM BORNE, ALBERT E. G., VAN DER SCHOOT, C. ELLEN, VAN LEEUWEN, ELEONORE F., SLAPER‐CORTENBACH, INEKE C. M.

“…Purging of autologous bone marrow (BM) grafts of children in second remission after a relapse of precursor B acute lymphoblastic leukaemia (ALL) in the BM has…”
Get full text

Fcγ receptor II (CD32) on malignant B cells influences modulation induced by anti-CD19 monoclonal antibody by VERVOORDELDONK, S. F, MERLE, P. A, VAN LEEUWEN, E. F, VAN DER SHOOT, C.E, VON DEM BORNE, A. E. G. K, SLAPER-CORTENBACH, I. C. M

“…Antigenic modulation is one of many factors determining the effectiveness of monoclonal antibody (MoAb)-mediated therapy. To select the isotype of a CD19 MoAb…”
Get full text

99m Tc-CD19 monoclonal antibody is not useful for imaging of B cell non-Hodgkin's lymphoma by Vervoordeldonk, Susan F., Heikens, Janneke, Goedemans, Wim T., Merle, Pauline A., von dem Borne, A. E. G. K., van Royen, Eric A., Slaper-Cortenbach, Ineke C. M., van Oers, Rien H. J.

Get full text

99mTc-CD19 monoclonal antibody is not useful for imaging of B cell non-Hodgkin's lymphoma by VERVOORDELDONK, S. F, HEIKENS, J, GOEDEMANS, W. T, MERLE, P. A, VON DEM BORNE, A. E. G. K, VAN ROYEN, E. A, SLAPER-CORTENBACH, I. C. M, VAN OERS, R. H. J

“…In this study we investigated the applicability of 99mTc-labeled CD19 monoclonal antibody (mAb) for tumor imaging in patients with B cell non-Hodgkin's…”
Get full text